MetLife Investment Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.4M | Buy |
165,913
+1,703
| +1% | +$24.4K | 0.01% | 961 |
|
|
2025
Q4 | $2.34M | Sell |
164,210
-1,145
| -0.7% | -$11.2K | 0.01% | 1004 |
|
|
2025
Q3 | $1.3M | Sell |
165,355
-7,723
| -4% | -$55K | 0.01% | 1310 |
|
|
2025
Q2 | $992K | Sell |
173,078
-979
| -0.6% | -$6.32K | 0.01% | 1319 |
|
|
2025
Q1 | $1.42M | Sell |
174,057
-5,498
| -3% | -$50.9K | 0.01% | 1203 |
|
|
2024
Q4 | $1.69M | Buy |
179,555
+10,056
| +6% | +$105K | 0.01% | 1132 |
|
|
2024
Q3 | $1.81M | Hold |
169,499
| – | – | 0.01% | 1069 |
|
|
2024
Q2 | $1.68M | Buy |
169,499
+24,389
| +17% | +$250K | 0.01% | 1062 |
|
|
2024
Q1 | $1.71M | Sell |
145,110
-3,556
| -2% | -$45.5K | 0.01% | 1032 |
|
|
2023
Q4 | $2.11M | Hold |
148,666
| – | – | 0.02% | 926 |
|
|
2023
Q3 | $1.81M | Hold |
148,666
| – | – | 0.01% | 946 |
|
|
2023
Q2 | $1.87M | Buy |
148,666
+2,243
| +2% | +$26.6K | 0.01% | 961 |
|
|
2023
Q1 | $1.62M | Hold |
146,423
| – | – | 0.01% | 988 |
|
|
2022
Q4 | $1.79M | Buy |
146,423
+947
| +0.7% | +$10.7K | 0.01% | 949 |
|
|
2022
Q3 | $1.52M | Hold |
145,476
| – | – | 0.01% | 995 |
|
|
2022
Q2 | $1.56M | Hold |
145,476
| – | – | 0.01% | 998 |
|
|
2022
Q1 | $1.38M | Buy |
145,476
+50,600
| +53% | +$474K | 0.01% | 1154 |
|
|
2021
Q4 | $1.1M | Hold |
94,876
| – | – | 0.01% | 1090 |
|
|
2021
Q3 | $906K | Hold |
94,876
| – | – | 0.01% | 1166 |
|
|
2021
Q2 | $915K | Buy |
94,876
+11,424
| +14% | +$112K | 0.01% | 1221 |
|
|
2021
Q1 | $825K | Sell |
83,452
-21,246
| -20% | -$329K | 0.01% | 1252 |
|
|
2020
Q4 | $2.42M | Sell |
104,698
-7,983
| -7% | -$163K | 0.02% | 732 |
|
|
2020
Q3 | $1.59M | Hold |
112,681
| – | – | 0.02% | 820 |
|
|
2020
Q2 | $1.7M | Hold |
112,681
| – | – | 0.02% | 793 |
|
|
2020
Q1 | $1.04M | Hold |
112,681
| – | – | 0.01% | 886 |
|
|
2019
Q4 | $1.1M | Hold |
112,681
| – | – | 0.01% | 1055 |
|
|
2019
Q3 | $904K | Buy |
112,681
+8,646
| +8% | +$93.8K | 0.01% | 1120 |
|
|
2019
Q2 | $1.3M | Buy |
104,035
+18,311
| +21% | +$232K | 0.01% | 993 |
|
|
2019
Q1 | $1.17M | Hold |
85,724
| – | – | 0.01% | 1018 |
|
|
2018
Q4 | $821K | Hold |
85,724
| – | – | 0.01% | 1098 |
|
|
2018
Q3 | $1.04M | Hold |
85,724
| – | – | 0.01% | 1104 |
|
|
2018
Q2 | $1.34M | Hold |
85,724
| – | – | 0.02% | 918 |
|
|
2018
Q1 | $1.29M | Buy |
85,724
+8,736
| +11% | +$133K | 0.02% | 914 |
|
|
2017
Q4 | $1.11M | Buy |
+76,988
| New | +$1.06M | 0.01% | 991 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
MetLife Investment Management's FOLD Position: Q1 2026 in Review
MetLife Investment Management increased its Amicus Therapeutics (FOLD) stake by 1% in Q1 2026, buying an estimated $24.4K and bringing the position to 165,913 shares worth $2.4M. The position accounts for 0.01% of the portfolio, ranked #961.
MetLife Investment Management first reported a position in FOLD in Q4 2017 and has held it in 34 quarters since. The position peaked at $2.42M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- MetLife Investment Management held 165,913 shares of Amicus Therapeutics worth $2.4M as of Q1 2026.
- MetLife Investment Management bought 1,703 Amicus Therapeutics shares in Q1 2026, an estimated $24.4K.
- Amicus Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #961 holding.
- MetLife Investment Management first reported a position in Amicus Therapeutics in Q4 2017 and has held it in 34 quarters since.
- MetLife Investment Management's Amicus Therapeutics position peaked at $2.42M in Q4 2020.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.